NeoRx responds to FDA:
This article was originally published in Clinica
NeoRx has submitted to the US FDA data from a phase II dosimetry study of its Skeletal Targeted Radiotherapy (STR) technique in patients with multiple myeloma, a cancer of the bone marrow. The dosimetry study was requested by the FDA to validate the patient-specific dosing method the company had used in earlier studies. NeoRx has also submitted to the agency a revised proposal for further clinical development of STR. "We believe that STR offers distinct advantages for transplant-eligible patients with multiple myeloma, a cancer that currently has no cure," says Douglass Given, president and CEO of the Seattle, Washington firm.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.